World Health Organization : Year 1993 ; World Health Organization Dbo Tfrd, No. 93.1: Report of the F I W Joint World Health Organizationn Task Force Meeting

By A. O. Adebajo

Book Id: WPLBN0000099886
Format Type: PDF eBook:
File Size: 1.0 MB
Reproduction Date: 2005

Title:	World Health Organization : Year 1993 ; World Health Organization Dbo Tfrd, No. 93.1: Report of the F I W Joint World Health Organizationn Task Force Meeting
Author:	A. O. Adebajo
Volume:
Language:	English
Subject:	Health., Public health, Wellness programs
Collections:	Medical Library Collection, World Health Collection
Historic Publication Date:
Publisher:	World Health Organization


Citation APA MLA Chicago O. Adebaj, B. A. (n.d.). World Health Organization : Year 1993 ; World Health Organization Dbo Tfrd, No. 93.1. Retrieved from http://gutenberg.cc/

Description
Medical Reference Publication

Excerpt
The meeting was opened by Dr N.G. Khaltaev on behalf of the Director-General. Dr Khaltaev welcomed the members of the Task Force to Geneva. Dr Khaltaev summarized the prepared remarks which noted that the rheumatic diseases were important to world health because they limit work performance and social integration. Osteoporosis has become the focus of public awareness as an important disease in public health, particularly because of high fracture rates and subsequent morbidity and mortality. Dr K.D. Muirden, President of ILAR, was elected Chair, Dr J.P. Edmonds, Secretary General of ILAR, was elected Vice-Chair, and both Dr P.M. Brooks and Dr C.H. Goldsmith were elected Rapporteurs. Dr Muirden extended thanks to Dr N.G. Khaltaev and his staff for their hard work in helping to coordinate the meeting. Dr A.S. Russell, Treasurer of ILAR, was most helpful in coordinating the relationships with the pharmaceutical industry.

Table of Contents
CONTENTS Page 1. INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2. DISEASE CONTROLLING ANTIRHEUMATIC THERAPYPC-ART) . . . . . . . . . . . . . 2 2.1 Improve and Sustain Function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2.2 Decrease Inflammatory Synovitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2.3 Prevent or Significantly Decrease Rate of Progression . . . . . . . . . . . . . . . . . . . 3 2.4 Are there Special Considerations Relevant to Trials of Biological Agents? . . . . . . . 3 3. SPECIAL CONSIDERATIONS OF DC-ARTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 3.1 Patient Stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 3.2 Changing Technologies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 3.3 Proportion of Response which Constitutes a Positive Response . . . . . . . . . . . . . . 4 3.4 Observational Studies vs Experiments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 4. TESTING PROTOCOLS FOR SLOW ACTING DRUGS FOR OSTEOARTHRITIS (OA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 4.1 Symptomatic Slow Acting Drugs for OA . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 4.2 Chondroprotective Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 4.3 Intra-articular Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 5. GUIDELINES FOR ANTIRHEUMATIC DRUG USE . . . . . . . . . . . . . . . . . . . . . . . . 7 6. PROTOCOL FOR TESTING SM-ARDS(NSA1DS) . . . . . . . . . . . . . . . . . . . . . . . . . . 7 7. WHOALAR CORE ENDPOINTS FOR SM-ARDS IN RHEUMATOID ARTHRITIS @A) CLINICALTRIALS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 8. RECOMMENDATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9